Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-effect relationship of remimazolam mesylate for adult gastroscopy
ChiCTR2200057446Phase 4Not yet recruiting
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam mesylate, sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoint: Induction dose of remimazolam. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
remimazolam mesylate
Beyond the preview
Go deeper on ChiCTR2200057446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057446.